Glatiramer Acetate

The acetate salt form of glatiramer, a disease-modifying therapy used to reduce the frequency of relapses in relapsing forms of multiple sclerosis. This polypeptide mixture acts as a decoy for the immune system, diverting the autoimmune attack away from myelin in the nervous system. It is available as a subcutaneous injection given daily or three times per week depending on the formulation.

Yes, Glatiramer Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.